Huons Global Co., Ltd. · KRX:084110
Huons Global — Q1 2024 Earnings Presentation
18 slides from Huons Global's earnings presentation, 2024
Slide 1: Huons Global Investor Relations 1Q 2024
Huons Global Investor Relations 1Q. 2024. 0/16
Slide 2: Disclaimer
Huons Global Disclaimer All information in this book including business performance and financial report is written by Korean-International Financial Reporting Standards(K-IFRS) . This book includes a “forecast” about future. It is not about the past, but the future business plan including expected
Slide 3: 01_ Company Summary 02_ Business Performance 03_ Subsidiaries
01_ Company Summary 02_ Business Performance 03_ Subsidiaries 04_ R&D 05_ Dividend Policy Appendix 2/16
Slide 4: Company Summary: Corporate Governance
1. Company Summary_Corporate Governance 1Q24 IR BOOK “Total Healthcare Group” Includes Pharma, Medical Devices, Health Functional Foods and Aesthetics business Huons Global (Holding company) Huons 41% Humedix 36% HuM&C 57% Huons 72% Huons 50% Huonslab 65% Food 50% 100% 100% Bio Pharma Meditech Assem
Slide 5: Company Summary: History
1. Company Summary_History 1Q24 IR BOOK Role within Huons Group - Set the strategy and direction of the group - Discovering new growth engines & Expanding business area - Growth through strategic M&A Huons + Strengthening HuM&C overseas business Biopharma Huons Huonslab + Healthcare subsidiaries Foo
Slide 6: Business Performance: Profit & Loss Analysis
2. Business Performance_Profit & Loss Analysis 1Q24 IR BOOK • Record high sales by continuing growth of major subsidiaries’ business (ETC, aesthetics) Sales Operating Profit Net Profit [Unit : billion KRW] [Unit : billion KRW] [Unit : billion KRW] [Sales] 18.9% 201.9 bil KRW (YoY ▲16.0%, QoQ ▲0.9%)
Slide 7: Business Performance: Subsidiaries' Profit & Loss Status
2. Business Performance_Subsidiaries’ Profit & Loss Status 1Q24 IR BOOK (Unit : Million KRW ) Sales Operating Profit Net Profit Classification 1Q24 1Q23 YoY 1Q24 1Q23 YoY 1Q24 1Q23 YoY Huons Global (Consolidated) 201,881 173,964 +16.0% 25,950 24,460 +6.1% 23,059 22,760 +1.3% Huons Global (Separated)
Slide 8: Subsidiaries: Huons
3. Subsidiaries_ Huons 1Q24 IR BOOK Business area : ETC with stable expanding to related businesses Financial Performance [Unit : Million KRW] Beauty ETC CMO Classifi- 1Q23 2Q23 3Q23 4Q23 1Q24 YoY QoQ Well-being cation ▪ Various medications ▪ Medications (non-reimbursable) ▪ Eye drops ETC 57,272 66,
Slide 9: Subsidiaries: Humedix
3. Subsidiaries_ Humedix 1Q24 IR BOOK Business area : Aesthetic and Pharmaceutical products using HA·PDRN Financial performance [Unit : Million KRW] Cosmetics· Classifi- Fiiler·Toxin ETC·CMO 1Q23 2Q23 3Q23 4Q23 1Q24 YoY QoQ etc. cation ▪ Beauty and healthcare ▪ Medications(non-reimbursable) ▪ Functi
Slide 10: Subsidiaries: HuM&C
3. Subsidiaries_ HuM&C 1Q24 IR BOOK Business area : Healthcare containers Financial performance Medical [Unit : Million KRW] Cosmetic Container Classifi- 1Q23 2Q23 3Q23 4Q23 1Q24 YoY QoQ ▪ Manufacturing medical ▪ Puff, sponge, container for ▪ Experiment equipment cation -glass containers make-up dis
Slide 11: Subsidiaries: Huons Biopharma, Huons Meditech
3. Subsidiaries_ Huons Biopharma, Huons Meditech 1Q24 IR BOOK Business area : Biopharmaceuticals including botulinum toxin Business area : Medical devices, Medical disinfectors, Sterilizers ➢ Continuing annual growth performance Therapy Beauty Others - Sales 8.2 bil KRW(YoY -24), OP 3.6 bil KRW (OPM
Slide 12: Subsidiaries: Huonslab, Huons USA, Huons JAPAN
3. Subsidiaries_ Huonslab, Huons USA, Huons JAPAN 1Q24 IR BOOK Subsidiary specialized in R&D of Biopharmaceuticals Local corp to expand businesses in the U.S. and North America ▪ Hold 6 types of biological drugs pipelines • Signed a contract to supply topical anesthetic (lidocaine) with McKesson ▪ R
Slide 13: R&D: Pipelines
4. R&D_Pipelines 1Q24 IR BOOK [As of Mar 31, 2024] Category Development Phase Project Indication Company Sector Discovery Preclinical Phase I Phase II Phase III Registration New Chemical HUC1-394 Dry eye Entities Huons HUC2-007 Dry eye Incrementally Modified Drug HUC2-344 Diabetes HMS1-049 Anticoagu
Slide 14: Dividend Policy
5. Dividend Policy 1Q24 IR BOOK Strengthening shareholder return policy • Implementation of a transparent and active shareholder return policy to increase corporate value • Implemented interim dividend / Increased dividend per share : Dividends twice a year / 2023 dividend of 525 KRW per share (YoY
Slide 15: Appendix: Business Performance (Yearly)
Appendix_Business Performance (Yearly) 1Q24 IR BOOK Sales Operating Profit Net Profit [Unit : billion KRW] [Unit : billion KRW] [Unit : billion KRW] 758.4 12.2% 15.0% 5.6% 664.4 12.9% 13.0% 113.9 -5.0% 574.6 92.6 86.5 74.3 32.1 -33.5 2021 2022 2023 2021 2022 2023 2021 2022 2023 14/16
Slide 16: Appendix: Board of Directors
Appendix_Board of Directors 1Q24 IR BOOK Board Members (As of Mar 31st, 2024) Soo-Young Song Sung-Tae Yoon In-Sang Yoon Kyu-yeon Lee Jin-Woo Chang Jong-Hyuk Bae President Chairman Position Director Outside Director Outside Director Outside Director C.E.O Director - President of Huons Group - Vice Ch
Slide 17: Appendix: Financial Statements
Appendix_Financial Statements 1Q24 IR BOOK Consolidated Statement of Financial Position Financial Statements of Comprehensive Income [Unit: million KRW] [Unit: million KRW] Classification 1Q23 2Q23 3Q23 4Q23 1Q24 Classification 1Q23 2Q23 3Q23 4Q23 1Q24 Assets 1,223,154 1,242,941 1,272,494 1,317,964
Slide 18: Thank you
Thank you